ESMO 2026 has ended. This guide stays up as the record of who was there. Next: ESMO 2027, Sep 17–21, 2027 in Barcelona
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences at ESMO 2026
Oct 23–27, 2026 Madrid, Spain ~37k attendees Website
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences takes part in 21 sessions at ESMO 2026 in Madrid. Its program focuses on treatment strategies across breast, lung and digestive cancers. It examines drug combinations and targeted treatments, including studies of therapies for HER2-positive and HER2-low advanced breast cancer.
| Organization | ESMO 2026 Attendance |
|---|---|
NC National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences Beijing, China | |
China's national cancer hospital and research centre in Beijing, part of the Chinese Academy of Medical Sciences and Peking Union Medical College. | Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Preoperative EGFR-TKI exposure and CNS progression patterns in surgically treated EGFR-mutant NSCLC brain metastases Lung & thoracic cancersSarcoma, CNS, head & neck and rare cancers Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Abstract Fri Oct 23 13:40–13:50 Abstract Fri Oct 23 14:35–14:45 Poster Fri Oct 23 15:15–16:00 Machine learning-driven plasma proteomic profiling for early detection of lung cancer in never-smokers: A large prospective cohort study Lung & thoracic cancersBiomarkers & precision oncology Abstract Sat Oct 24 08:30–08:35 Abstract Sat Oct 24 09:25–09:35 Abstract Sat Oct 24 09:35–09:45 Poster Sat Oct 24 12:00–12:45 Poster Sat Oct 24 12:00–12:45 Poster Sat Oct 24 12:00–12:45 Poster Sat Oct 24 12:00–12:45 Poster Sat Oct 24 12:00–12:45 Poster Sun Oct 25 12:00–12:45 Poster Sun Oct 25 12:00–12:45 Health-related quality of life in the phase 3 ASTRUM-007 study of serplulimab or placebo plus chemotherapy for PD-L1-positive oesophageal squamous cell carcinoma Gastrointestinal cancersNursing & supportive care Poster Sun Oct 25 12:00–12:45 ctDNA-based MRD status refines risk stratification and may inform adjuvant chemotherapy decisions in stage II colorectal cancer: An updated analysis of the PROTECTOR-C study Gastrointestinal cancersBiomarkers & precision oncology Poster Mon Oct 26 12:00–12:45 A conserved multimodal tumor microenvironment classifier predicts prognosis and chemoimmunotherapy benefit in small-cell lung cancer Lung & thoracic cancersBiomarkers & precision oncology Poster Mon Oct 26 12:00–12:45 Poster Mon Oct 26 12:00–12:45 Health-related quality of life in the phase 3 trial ASTRUM-002 of serplulimab plus chemotherapy with or without HLX04 for nonsquamous non-small cell lung cancer Lung & thoracic cancersNursing & supportive care Poster Mon Oct 26 12:00–12:45 Neoadjuvant tislelizumab plus chemotherapy followed by adjuvant tislelizumab for locally advanced nasopharyngeal carcinoma: Updated analysis Sarcoma, CNS, head & neck and rare cancers Poster Mon Oct 26 12:00–12:45 Poster Mon Oct 26 12:00–12:45 Poster Mon Oct 26 12:00–12:45 |
Find decision makers at National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences
Tell us what you sell and we’ll find the people at National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction